What Is NDMA and How Did It Get Into Zantac?
N-nitrosodimethylamine (NDMA) is a chemical classified as a probable human carcinogen (Group 2A) by the International Agency for Research on Cancer. NDMA is found naturally in trace quantities in some foods, water, and the environment, but chronic exposure to elevated levels has been consistently linked to cancer in both animal and human studies. The FDA sets an acceptable daily intake limit for NDMA of 96 nanograms per day — a conservative threshold designed to ensure lifetime exposure from all sources carries negligible cancer risk. The Zantac crisis is distinct from earlier NDMA contamination scandals in blood pressure medications like valsartan. In those cases, NDMA was an external contaminant introduced during a specific manufacturing process. In ranitidine, NDMA is an intrinsic breakdown product of the drug molecule itself.
The Chemistry of Ranitidine Instability
Ranitidine's molecular structure contains a dimethylaminomethyl group — a chemical moiety that can rearrange and fragment under thermal, pH, and oxidative conditions to yield NDMA. This degradation is not unusual or anomalous; it is an inherent feature of the ranitidine molecule's chemistry. The key findings from Valisure's 2019 research and subsequent independent studies are: (1) NDMA levels in ranitidine tablets increase progressively as the tablets age and when stored at higher temperatures; (2) When ranitidine is dissolved and heated to simulate stomach and body temperatures, NDMA generation accelerates dramatically; (3) Following oral ingestion, ranitidine undergoes metabolic transformation in the gastrointestinal tract and liver, generating NDMA directly inside the body at the site of the organs most at risk — stomach, colorectal tissue, and the urinary tract through renal excretion.
What Valisure Found and Why It Matters
Valisure LLC tested multiple Zantac lots and found NDMA levels as high as 304,500 nanograms per tablet — 3,172 times the FDA's 96-nanogram daily acceptable intake. Valisure also demonstrated that NDMA levels increased substantially when ranitidine was tested under simulated body conditions. A subsequent 2020 study from Stanford University researchers, using a method designed to more closely simulate in vivo ranitidine metabolism, found that a single 150 mg ranitidine dose generated NDMA levels in urine of over 47,000 nanograms — orders of magnitude above the safe limit. These findings established that the safety concern was not limited to degraded or improperly stored pills; every dose of ranitidine generated problematic NDMA levels in the human body.
Why This Problem Could Not Be Fixed by Manufacturers
Unlike NDMA contamination from a specific manufacturing reagent — which can potentially be addressed by changing the synthesis process — the NDMA problem in ranitidine cannot be resolved by reformulation or manufacturing changes without fundamentally altering the ranitidine molecule itself. The instability is inherent to the active pharmaceutical ingredient. This is why the FDA did not issue guidance on remediation or manufacturing process changes; instead, it went directly to requesting full market withdrawal of all ranitidine products. There is no safe version of ranitidine, and the FDA has stated it will not accept new drug applications for ranitidine products. Famotidine (Pepcid), cimetidine (Tagamet), and proton pump inhibitors (omeprazole, lansoprazole) are pharmacologically similar alternatives that do not generate NDMA and are widely available.
Frequently Asked Questions
Related Pages
The Valisure Study — How the NDMA Problem Was Discovered
Valisure LLC, an independent pharmaceutical testing laboratory in New Haven, Connecticut, discovered the NDMA problem in ranitidine in 2019 and filed a Citizen Petition with the FDA that triggered the events leading to the April 2020 market withdrawal. Valisure's methodology was initially contested but has been substantially vindicated by subsequent independent research.
Zantac Settlement Expectations — State Court Litigation 2026
Zantac state court litigation in 2026 is in an active but early phase compared to fully mature mass torts. Bellwether trials in Delaware will begin to establish settlement values for the broader case pool. Settlement ranges of $200,000 to $3,000,000 are estimated for qualifying claims, with strong Stage IV/wrongful death cases commanding the highest values. Do not expect quick settlements — state court mass torts typically take years.
Zantac Statute of Limitations — State-by-State 2026 Analysis
The statute of limitations for Zantac cancer claims varies by state, typically 2 to 3 years from the date of cancer diagnosis or from when the claimant knew or should have known of the Zantac-cancer connection (the discovery rule). The April 2020 FDA withdrawal is often cited as the constructive notice date. Claimants with diagnoses from 2022 onward and those who can show delayed discovery may still have timely claims in 2026.
Cancers Covered by Zantac Litigation
Six cancer types are the primary qualifying diagnoses in active Zantac state court litigation in 2026: bladder, stomach, colorectal, esophageal, breast, and prostate cancers. Bladder and gastrointestinal cancers have the most robust scientific and epidemiological support. Strength of causation evidence and state court acceptance varies by cancer type, and an attorney can evaluate your specific diagnosis.
Zantac and Bladder Cancer
Bladder cancer is the cancer most strongly and consistently linked to NDMA exposure from ranitidine. NDMA is excreted in urine, directly bathing the bladder epithelium in the carcinogen. Bladder cancer carries a high recurrence rate even after successful treatment, meaning lifetime surveillance and repeat procedures create substantial ongoing medical costs that factor significantly into claim values.
Zantac Federal MDL Dismissal — What Happened
The federal MDL in the Southern District of Florida was dismissed in November 2022 after Judge Robin Rosenberg excluded all of the plaintiffs' general causation experts under the Daubert standard. This ruling applies only to federal court. It does not bind state courts. Active Zantac litigation continues in Delaware and California state courts in 2026 under different evidentiary standards.
Zantac State Court Litigation — Delaware and California 2026
Following the closure of the federal MDL in November 2022, Zantac litigation has continued and grown in state courts. Delaware Superior Court is the most active venue, with thousands of consolidated cases proceeding under coordinated case management orders. California state courts have also produced favorable rulings for plaintiffs. State court proceedings are independent of the federal MDL and proceed on their own timelines in 2026.
Zantac Eligibility Requirements
To qualify for a Zantac cancer claim in 2026, you generally need: (1) at least 1 year of regular Zantac or ranitidine use; (2) a diagnosis of a qualifying cancer type; (3) a medically plausible timeline between use and diagnosis; and (4) a claim that falls within your state's statute of limitations. State court filings are active in Delaware and California.
Zantac Brand vs. Generic — All Manufacturers Are Liable
The NDMA problem is inherent to the ranitidine molecule, not to any specific manufacturer or formulation. Branded Zantac (Sanofi, and previously GSK and Pfizer), generic ranitidine from Boehringer Ingelheim and others, and all store-brand versions carry the same risk. All ranitidine manufacturers are named defendants in Zantac litigation.
FDA Zantac Market Withdrawal — April 2020
On April 1, 2020, the FDA formally requested that all ranitidine manufacturers withdraw their products from the U.S. market. This unprecedented action — covering both prescription and OTC products from all manufacturers — marked the FDA's conclusion that the NDMA problem in ranitidine was unfixable and that ranitidine products posed an unacceptable cancer risk for consumers.
Proving Zantac Use — How to Obtain Pharmacy Records
Pharmacy records are the single strongest form of evidence of long-term Zantac use for litigation purposes. Major pharmacy chains maintain prescription records and often OTC purchase histories for many years. Your attorney can assist in obtaining these records through HIPAA authorizations and subpoenas.
Zantac / Ranitidine (NDMA Cancer) Lawsuit
Ranitidine, sold under the brand name Zantac by Sanofi and previously by GSK, Pfizer, and Boehringer Ingelheim, was one of the most prescribed heartburn and acid reflux medications in history. In 2019, the independent pharmaceutical testing laboratory Valisure discovered that ranitidine is inherently unstable and produces NDMA — N-nitrosodimethylamine, a probable human carcinogen — at levels up to 304,500 nanograms per tablet. The FDA acceptable daily intake limit for NDMA is 96 nanograms. In April 2020, the FDA requested that all manufacturers withdraw ranitidine products from the U.S. market. Consumers who took Zantac regularly for a year or more and subsequently developed bladder, stomach, colorectal, breast, prostate, or esophageal cancer may have viable legal claims. A federal MDL in the Southern District of Florida was dismissed in November 2022 when Judge Robin Rosenberg excluded plaintiffs' general causation experts under Daubert, finding their methodologies unreliable. However, that ruling applies only to federal court and does not bind state courts. Litigation continues in Delaware Superior Court and California state courts in 2026, where different expert standards and case-specific evidence can support claims.
View full case overview